KDMN
(NYSE)
4.28
-0.0298  (-0.70%)
Volume (24h): 380.74K Day Range: 4.19 - 4.39
Market Cap: 684.91M 52W Range: 1.63 - 5.49
Jun-01-20 01:56PM 3 “Strong Buy” Biotech Stocks Under $5 With Major Catalysts ApproachingTipRanks
May-27-20 12:00PM Kadmon to Present at the Jefferies 2020 Virtual Global Healthcare ConferenceACCESSWIRE
May-21-20 05:35PM Why Kadmon Holdings Jumped TodayMotley Fool
11:25AM Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host DiseaseACCESSWIRE
May-19-20 08:08PM 7 Biotech Stocks Wall Street Says Will Double or MoreKiplinger
May-11-20 10:52AM H.C. Wainwright Sticks to Their Buy Rating for Kadmon HoldingsInvesting.com
May-10-20 02:50PM Analysts Have Lowered Expectations For Kadmon Holdings, Inc. (NYSE:KDMN) After Its Latest ResultsSimply Wall St.
May-07-20 08:14PM Kadmon Provides Business Update and Reports First Quarter 2020 Financial ResultsACCESSWIRE
Apr-14-20 01:20PM Is Kadmon Holdings, Inc. (NYSE:KDMN) Overpaying Its CEO?Simply Wall St.
11:59AM Kadmon Announces Receipt of Final Meeting Minutes from FDA Following Pre-NDA Meeting for KD025 for the Treatment of cGVHDACCESSWIRE
Mar-13-20 08:15PM Kadmon Announces Update on pre-NDA Meeting with FDA and Provides Business UpdateACCESSWIRE
Mar-09-20 05:57PM Here's Why We're Not Too Worried About Kadmon Holdings's (NYSE:KDMN) Cash Burn SituationSimply Wall St.
Mar-05-20 09:14PM Kadmon Highlights Recent Progress and Reports Fourth Quarter and Full Year 2019 Financial ResultsGlobeNewswire
Feb-23-20 11:38PM The Week Ahead In Biotech: Biopharma Earnings Pick Up PaceBenzinga
05:29PM Kadmon Announces Expanded Results of Interim Analysis of Pivotal Trial of KD025 in cGVHDACCESSWIRE
Jan-22-20 02:33PM 3 Healthcare Stocks With Important Catalysts in Q1TipRanks
Jan-10-20 09:15PM Kadmon Announces Acceptance of Late-Breaking Abstract of KD025 for cGVHD at the 2020 TCT MeetingsACCESSWIRE
Jan-06-20 01:34PM Investors Who Bought Kadmon Holdings (NYSE:KDMN) Shares A Year Ago Are Now Up 90%Simply Wall St.
Dec-26-19 01:40PM Implied Volatility Surging for Kadmon (KDMN) Stock OptionsZacks
01:00PM Kadmon and Meiji Announce Collaboration to Develop and Commercialize KD025 in JapanACCESSWIRE
Dec-13-19 12:38AM Hedge Funds Have Never Been More Bullish On Kadmon Holdings, Inc. (KDMN)Insider Monkey
Dec-07-19 01:35PM The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom RulingBenzinga
Dec-03-19 01:00PM Kadmon to Present Updated Data from Phase 2 Study of KD025 in cGVHD at the 61st ASH Annual Meeting & ExpositionACCESSWIRE
Nov-22-19 05:13PM Largest Insider Trades of the WeekGuruFocus.com
Nov-18-19 09:15PM Kadmon Announces Closing of $101.6mm Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional SharesACCESSWIRE
01:15PM Kadmon to Participate in Upcoming Investor ConferencesACCESSWIRE
Nov-14-19 01:50AM Kadmon Announces Pricing of Public Offering of Common StockACCESSWIRE
Nov-13-19 09:25PM Kadmon Announces Proposed Public Offering of Common StockACCESSWIRE
Nov-12-19 03:39PM Kadmon biopharma shares rise on interim trial resultsMarketWatch
12:20PM The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings BeatBenzinga
Nov-11-19 09:24PM Kadmon Announces that KD025 Met Primary Endpoint at Interim Analysis of Pivotal Trial in Chronic Graft-Versus-Host DiseaseACCESSWIRE
Nov-08-19 03:57PM Hedge Funds Have Never Been More Bullish On Kadmon Holdings, Inc (KDMN)Insider Monkey
Nov-07-19 09:15PM Kadmon Establishes Strategic Partnership with BioNova to Develop and Commercialize KD025 for the Treatment of GVHD in ChinaACCESSWIRE
Oct-21-19 08:14PM Kadmon Announces FDA Approval of CLOVIQUE (TM), A Room-Temperature Stable Trientine Hydrochloride ProductACCESSWIRE
Oct-07-19 07:19PM Does Kadmon Holdings, Inc.'s (NYSE:KDMN) CEO Salary Compare Well With Others?Simply Wall St.
Oct-03-19 12:00PM Kadmon Announces Sale of 1.4 Million Shares of MeiraGTx Holdings plcACCESSWIRE
Sep-23-19 12:00PM Kadmon to Participate in Upcoming Investor ConferencesACCESSWIRE
Sep-17-19 08:15PM Kadmon Announces FDA Approval of Generic Trientine HydrochlorideACCESSWIRE
Sep-07-19 04:19PM 3 Biotech Stocks That Could Double Your MoneyMotley Fool
Aug-30-19 08:15PM Kadmon Announces Appointment of Gregory S. Moss as Executive Vice President, General Counsel and Corporate SecretaryACCESSWIRE
Aug-23-19 03:10PM Is Kadmon Holdings (NYSE:KDMN) Using Too Much Debt?Simply Wall St.
Aug-14-19 01:10PM Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHDZacks
Aug-13-19 12:00PM Kadmon Fully Enrolls Pivotal Trial of KD025 for Chronic Graft-Versus-Host DiseaseACCESSWIRE
Aug-05-19 08:14PM Kadmon Provides Business Update and Reports Second Quarter 2019 Financial ResultsACCESSWIRE
Aug-01-19 02:33PM Will Kadmon Holdings (KDMN) Report Negative Q2 Earnings? What You Should KnowZacks
Jul-18-19 07:47PM If You Had Bought Kadmon Holdings (NYSE:KDMN) Stock A Year Ago, You'd Be Sitting On A 22% Loss, TodaySimply Wall St.
Jul-11-19 03:19PM Moleculin Files New Patents for Cancer Candidate AnnamycinZacks
Jul-10-19 09:51PM Kadmon Initiates Dosing in Study for Systemic Sclerosis DrugZacks
Jul-09-19 08:14PM Kadmon Doses First Patient in Phase 2 Clinical Trial of KD025 in Systemic SclerosisACCESSWIRE
Jun-24-19 01:44AM Hedge Funds Have Never Been This Bullish On Kadmon Holdings, Inc. (KDMN)Insider Monkey
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; ROCK inhibitor platform, a rho-associated coiled-coil kinase inhibitor, which is in preclinical development to treat specific fibrotic and neurodegenerative diseases; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)